FTC, States Ask Court to Hold 'Pharma Bro' Shkreli in Contempt for Trading Drug Stocks
- FTC plus seven states demand a contempt ruling, claiming Shkreli violated his lifetime pharma-industry ban by trading drug stocks again.
- The 'Pharma Bro' — already a convicted felon — apparently treats a permanent industry ban like a polite suggestion, not a court order.
- Regulators say his trading isn't just illegal, it's a deliberate middle finger to the judge who thought they'd finally shut him up.
- If held in contempt, Shkreli could face fresh fines or even more jail time — the one thing that actually seems to slow him down.
- The case screams a grim truth: the drug industry's bad boys don't reform; they just get better at hiding their moves.
Brief Summary
In the latest episode of 'Martin Shkreli: Legal Whack-A-Mole,' the FTC and seven states have marched back to court to demand the notorious 'Pharma Bro' be held in contempt for allegedly violating his lifetime ban from the drug industry. Turns out, when a judge tells this guy to stay out of pharma forever, Shkreli hears 'trade pharma stocks, but don't get caught.' Regulators claim he's been quietly dabbling in drug company shares, apparently unable to resist the siren call of price-gouging-adjacent investments.
The man who once hiked a life-saving drug's price by 5,000% is now accused of treating a federal ban like a temporary inconvenience. The FTC and states want Judge Denise Cote to lower the hammer, arguing that Shkreli's stock trading isn't just a technical violation — it's a brazen poke in the eye to the legal system that already locked him up once. This isn't about a reformed man making a mistake; it's about a serial troll who sees regulations as suggestions and probably giggles every time he clicks 'buy.'
Why This Matters
For the average reader, this story isn't just celebrity-adjacent gossip — it's a stark reminder that the pharmaceutical industry's worst actors don't go quietly into the night. Shkreli's alleged defiance shows that corporate bans and lifetime injunctions are only as strong as the judges willing to enforce them. When a guy like this can flout a federal order and force regulators to beg for a contempt ruling, it underlines how much red tape is required to keep bad actors away from your medicine cabinet.
More importantly, this affects your wallet and your health. Shkreli's stock trading might seem like rich-guy games, but his history of price-gouging proves his influence on drug costs is real. If he's back in the game, even on the sidelines, it signals that the system still struggles to police the very people who've shown they'd sell your grandmother's asthma medication for a profit. Pay attention: this isn't about one obnoxious 'bro' — it's a test of whether the FDA, FTC, and courts can actually protect consumers from the industry's wolves.